IP Library Granted Patent US 11,730,768
Granted Patent B2
US 11,730,768 · App. 16/668,851 · Granted Aug 22, 2023

Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids

Inventors: Evangelos V. Badiavas (Coral Gables, FL); Arsalan Q. Shabbir (Miami, FL); Stephen C. Davis (El Portal, FL)
Assignee: UNIVERSITY OF MIAMI
A61K35/28A61K8/981A61K8/983A61K35/12A61K35/16A61K35/22A61Q19/00A61Q19/08A61K2800/74A61K2800/86
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,730,768
App. No.
16/668,851
Granted
Aug 22, 2023
Kind
B2
Abstract

The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Claims (23)

1. A topical composition for treating wounds comprising an effective amount of an enriched population of intact microvesicles collected from polyethylene glycol precipitation of a mesenchymal stem cell supernatant or a biological fluid;

wherein the mesenchymal stem cells are derived from bone marrow;

wherein the microvesicles range in size from 2 nm to 5000 nm;

wherein the topical composition further comprises a storage solution;

wherein the intact microvesicles result in increased migration of non-proliferating cultured fibroblasts in a cell migration assay when administered to the non-proliferating cultured fibroblasts; and

wherein said effective amount of isolated microvesicles results in regeneration of at least one skin tissue in the skin wound.

2. The topical composition of claim 1 , wherein the microvesicles are heterogeneous in size and shape and comprise ectosomes, exosomes, microparticles, microvesicles, nanovesicles, shedding vesicles, apoptotic bodies, and/or membrane particles.

3. The topical composition of claim 1 , wherein the microvesicles do not provoke a significant inflammatory response when administered to the wound a subject.

4. The topical composition of claim 1 , wherein the microvesicles range in size from 2 nm to 200 nm.

5. The topical composition of claim 1 , wherein the microvesicles have a molecular weight of at least 100 kDa.

6. The topical composition of claim 1 , wherein administration of the topical composition to the wound of a subject results in a reduction of wrinkle formation or scar formation in skin of the wound of the subject.

7. The topical composition of claim 1 , wherein the microvesicles express the exosomal markers HSP 70, CD63, and STAT3.

8. The topical composition of claim 1 , wherein the microvesicles contain at least one molecule selected from the group consisting of RNA, DNA, lipids, carbohydrates, drugs, small molecules, peptides, metabolites, and proteins from a host cell.

9. The topical composition of claim 8 , wherein the host cell is engineered to express the at least one RNA, DNA, peptide, or protein molecule.

10. The topical composition of claim 1 , wherein the composition is formulated for topical administration.

11. A topical composition for treating wounds comprising an effective amount of an enriched population of intact microvesicles, comprising ectosomes, exosomes, microparticles, microvesicles, nanovesicles, shedding vesicles, apoptotic bodies, and/or membrane particles;

wherein the topical composition further comprises a buffer or stabilization solution;

wherein the microvesicles are isolated from polyethylene glycol precipitation of a bone marrow mesenchymal stem cell supernatant or a biological fluid;

wherein the microvesicles comprise a size ranging from 2 nm to 5000 nm;

wherein the intact microvesicles result in increased migration of non-proliferating cultured fibroblasts in a cell migration assay when administered to the non-proliferating cultured fibroblasts; and

wherein said effective amount of isolated microvesicles results in regeneration of at least one skin tissue in the skin wound.

12. The topical composition of claim 11 , wherein the isolated microvesicles have a molecular weight of at least 100 kDa.

13. The topical composition of claim 11 , wherein the composition is formulated for topical administration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2023
From: BADIAVAS, EVANGELOS V.; SHABBIR, ARSALAN Q.; DAVIS, STEPHEN C.
To: UNIVERSITY OF MIAMI
Reel/Frame 063905/0990 →
Continuity (3)
Continuation 14775382
Provisional Application 61778591 · Mar 13, 2013
Related Publication 20200163999A1 · May 28, 2020
Cited By (2)
US 12,453,745 US 12,558,316